$Turnstone Biologics (TSBX.US)$ 🤔 this coming week or two should be interesting I will be looking at this one this week

$Trio Petroleum (TPET.US)$ $Kingsoft Cloud (KC.US)$ $Greenwave Technology Solutions (GWAV.US)$ $Algorhythm (RIME.US)$ $Turnstone Biologics (TSBX.US)$ $ProShares Short Ether ETF (SETH.US)$ $TCTM Kids IT Education (TCTM.US)$ $SilverBox Corp IV (SBXD.US)$ $Triumph (TGI.US)$ $Quest Resource Holding (QRHC.US)$ $Blue Hat Interactive Entertainment Technology (BHAT.US)$ $ProShares UltraShort Ether ETF (ETHD.US)$ $Reborn Coffee (REBN.US)$ $MDJM Ltd (UOKA.US)$
📊⚡️📊

$Blackboxstocks (BLBX.US)$ $SAG Holdings (SAG.US)$ $New Horizon Aircraft (HOVR.US)$ $CleanCore Solutions (ZONE.US)$ $Algorhythm (RIME.US)$ $Jianzhi Education (JZ.US)$ $Akari Therapeutics (AKTX.US)$ $Turnstone Biologics (TSBX.US)$ $Radiopharm Theranostics (RADX.US)$ $SaverOne 2014 (SVRE.US)$ $MDJM Ltd (UOKA.US)$ $ProPhase Labs (PRPH.US)$ $Society Pass (SOPA.US)$ $Blue Hat Interactive Entertainment Technology (BHAT.US)$ $Portage Biotech (PRTG.US)$
📊⚡️📊

$Turnstone Biologics (TSBX.US)$ watching now in the low/mid 40 cents

$Turnstone Biologics (TSBX.US)$ 2

$Turnstone Biologics (TSBX.US)$
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics (NASDAQ: TSBX)presented preclinical data on their Selected TIL technology at the 2024 SITC Annual Meeting. The research focuses on selectively expanding tumor-reactive T cells for solid tumor treatment. Two key studies were presented...

$Turnstone Biologics (TSBX.US)$ why falling like this

$Turnstone Biologics (TSBX.US)$
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Corp. (Nasdaq: TSBX) reported Q2 2024 financial results and business highlights. Key points include:
1. Positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, with a 25% overall response rate and 50% disease control rate.
2. Cash position of $62.4 million, expected to fund operations into Q...

$Turnstone Biologics (TSBX.US)$
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Turnstone Biologics Corp. (Nasdaq: TSBX) reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (MSS mCRC). Key findings include:
- 25% overall response rate (ORR) and 50% disease control rate (DCR) among four evaluable patients
- One patient achieved a deep and durable o...